How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics

Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B.

In this episode, we discuss:
 • Why Gilgamesh is building psychedelic medicines the way large pharma would
 • The thesis behind short-acting psychedelics and why long-duration trips are impractical for real-world psychiatry
 • How Gilgamesh designs molecules backwards from clinical needs
 • Effective approaches to the challenges of trial designs for psychedelics 
 • What AbbVie’s deal and Spravato’s trajectory mean for psychedelics
 • How psychedelic medicines could reshape mental health

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias and Greg
Produced by Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank